c-MYC overexpression overrides TAK1 dependency in efficient tumorigenicity of AKT-transformed cells

Cancer Lett. 2013 Aug 19;336(2):290-8. doi: 10.1016/j.canlet.2013.03.014. Epub 2013 Mar 21.

Abstract

Transforming growth factor activated kinase 1 (TAK1) provides prosurvival signals in various types of cells, and emerging evidence indicates that targeting TAK1 is a promising means to eliminate certain types of cancer cells. Here, we show that TAK1 is required for efficient tumorigenicity of AKT-transformed cells. TAK1 inhibition accelerates cell apoptosis of AKT-transformed cells in anchorage-independent cell growth accompanying by the downregulation of Mcl-1 and Bcl-2 expression. On the contrary, the tumorigenicity of c-Myc-transformed cells is not significantly affected by TAK1 inhibition. Moreover, AKT-transformed cells with c-Myc overexpression tolerate TAK1 inhibition in anchorage-independent growth and tumorigenicity in vivo. Together, our results provide evidence that TAK1-dependency in the tumorigenicity of AKT-transformed cells can be alleviated by c-Myc overexpression. These findings suggest that dual-targeting TAK1 and c-Myc might be a rational therapeutic strategy for treatment of certain types of cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / physiology
  • Cell Growth Processes / physiology
  • Cell Survival / physiology
  • Cell Transformation, Neoplastic / metabolism
  • Fas-Associated Death Domain Protein / metabolism
  • Gene Knockdown Techniques
  • Humans
  • MAP Kinase Kinase Kinases / antagonists & inhibitors*
  • MAP Kinase Kinase Kinases / deficiency
  • MAP Kinase Kinase Kinases / genetics
  • MAP Kinase Kinase Kinases / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Mice, Nude
  • Mice, Transgenic
  • NIH 3T3 Cells
  • Proto-Oncogene Proteins c-akt / metabolism*
  • Proto-Oncogene Proteins c-bcl-2 / biosynthesis
  • Proto-Oncogene Proteins c-myc / biosynthesis*
  • Proto-Oncogene Proteins c-myc / metabolism
  • TNF-Related Apoptosis-Inducing Ligand / pharmacology
  • Xenograft Model Antitumor Assays

Substances

  • Fas-Associated Death Domain Protein
  • Proto-Oncogene Proteins c-bcl-2
  • Proto-Oncogene Proteins c-myc
  • TNF-Related Apoptosis-Inducing Ligand
  • Proto-Oncogene Proteins c-akt
  • MAP Kinase Kinase Kinases
  • MAP kinase kinase kinase 7